Page 48 - ESHRE2019

Borderline Ovarian Tumors are of Low Malignant Potential
General considerations
 Stage I is 5y survival is 99% of patients
 USO is an option for women with unilateral
disease
 Even in advanced Stage, high recurrence rate
but limited mortality
 Recurrence after conservative surgery 7 to 30%
 Recurrences typically show borderline histology,
not invasive carcinoma
 If no malignant disease is present, borderline
recurrences are not associated with mortality
BOC recurrence after FSS
• Stage I BOC treated with either
‐ USO or ovarian cystectomy was 13 %
‐ after USO ‐ 7%, after cystectomy was 23%, Death rate was 0.5%
• After a recurrence, the uterus and one ovary or part of an ovary may be conserved to retain fertility
• Patients with stage I to III disease, tumor recurrence rates after
• TAH‐BSO is 6%
• Adnexectomy15%
• Cystectomy 36%
• Women with stage II ‐ IV serous borderline tumors, 6% reports of invasive recurrences
46
43